Nippon Boehringer Ingelheim has launched Domin (talipexole) onto the Japanese market for the treatment of Parkinson's disease. This is the first world launch for the product, a selective alpha2/dopamine D2 receptor agonist.
Talipexole comes in 0.4mg tablets (costing 215.8 yen [$1.94] per tablet), and the recommended starting dose range is 0.2mg-0.4mg once-daily, rising to a maximum dose of 3.6mg. Daily doses above 0.8 mg should be given twice-daily, while doses above 3.6mg should be given three times-daily. The drug is indicated for administration either alone or in combination with levodopa.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze